101
Views
1
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials

, , &
Pages 257-263 | Received 06 Mar 2021, Accepted 07 Apr 2021, Published online: 19 Apr 2021
 

Abstract

Background

Previous meta-analyses comparing major bleeding of uninterrupted non-vitamin K antagonist oral anticoagulants (NOACs) versus uninterrupted vitamin K antagonist (VKA) during catheter ablation (CA) of atrial fibrillation (AF) had no consensus. This meta-analysis was performed to comprehensively evaluate the risk of major bleeding events of these two anticoagulant strategies.

Methods

We searched online databases for randomised controlled trials that compared major bleeding events of uninterrupted NOACs and VKA during CA of AF. A fixed-effect model was used if P-value was > 0.10 and I2 was < 50%, otherwise a random- effect model was used.

Results

Six studies including 2392 patients were included in the analysis. The incidence of major bleeding was lower in the NOACs group than in the VKA group (OR = 0.56, 95% CI = 0.34 − 0.93, I2 = 38%, p = 0.15). Subgroup analyses showed that the incidence of severe puncture site complications was lower in the NOACs group than in the VKA group (OR = 0.53, 95% CI = 0.30 − 0.96, I2 = 16%, p = 0.32). But the incidence of cardiac tamponade (OR = 0.53, 95% CI = 0.23 − 1.26, I2 = 0%, p = 0.46), intracranial (OR = 0.25, 95% CI = 0.03 − 2.23, I2 = 0%, p = 0.82) and gastrointestinal bleeding (OR = 0.98, 95% CI = 0.18 − 5.39, I2 = 0%, p = 0.43) had no statistically differences between the two groups.

Conclusion

This meta-analysis suggests that compared to uninterrupted VKA, uninterrupted NOACs are superior in major bleeding during CA of AF, but this superiority existed only in the aspect of severe puncture site complications.

Disclosure statement

There was no direct support from any organisation or industry company for the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.